Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 12-12 15:00:00

28.28

-0.26

-0.91%

High28.59	Low28.01	Vol20.05M
Open28.50	D1 Closing28.54	Amplitude2.03%
Mkt Cap75.51B	Tradable Cap59.90B	Total Shares2.67B
T/O567.00M	T/O Rate0.95%	Tradable Shares2.12B
P/B1.57	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":28.28,"timestamp":1765522800000,"preClose":28.54,"halted":0,"volume":20054921,"delay":0,"changeRate":-0.0091,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"Closed","change":-0.26,"latestTime":"12-12 15:00:00","open":28.5,"high":28.59,"low":28.01,"amount":567000000,"amplitude":0.0203,"askPrice":28.29,"askSize":147,"bidPrice":28.28,"bidSize":773,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":5,"adr":0,"adjPreClose":28.54,"symbolType":"stock","openAndCloseTimeList":[[1765503000000,1765510200000],[1765515600000,1765522800000]],"highLimit":31.39,"lowLimit":25.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.57,"roa":"--","peRate":23.004962,"roe":"5.3%","epsLYR":1.04,"committee":-0.145637,"marketValue":75520000000,"turnoverRate":0.0095,"status":1,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":22.36,"timestamp":1765525579334,"preClose":22.28,"halted":0,"volume":3853557,"delay":0,"premium":"-28.36"},"floatMarketCap":59911000000},"requestUrl":"/m/hq/s/600196/tweets","defaultTab":"tweets","newsList":[{"id":"2590981585","title":"BRIEF-Shanghai Fosun Pharma Says Foscarnet Sodium Injection Of Unit Approved By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2590981585","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590981585?lang=en_us&edition=fundamental","pubTime":"2025-12-10 18:20","pubTimestamp":1765362046,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Says Foscarnet Sodium Injection Of Unit Approved By NMPADec 10 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:FOSCARNET SODIUM INJECTION OF UNIT APPROVED BY NMPAFurther company coverage: 600196.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG04A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0239","BK0028","BK0187","BK0196","BK0188","BK0183","BK0175","BK0060","BK0096","600196"],"gpt_icon":0},{"id":"2590600585","title":"Shanghai Fosun Pharma -  Foscarnet Sodium Injection of Unit Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2590600585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590600585?lang=en_us&edition=fundamental","pubTime":"2025-12-10 18:19","pubTimestamp":1765361990,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nFWN3XG04A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0196","BK0239","BK0060","BK0175","BK0183","BK0188","600196","BK0012","BK0096","BK0187","BK0028"],"gpt_icon":0},{"id":"1171314906","title":"Capital Securities Maintains \"Buy\" Rating on Fosun Pharma (02196) with Target Price of HK$26.5","url":"https://stock-news.laohu8.com/highlight/detail?id=1171314906","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171314906?lang=en_us&edition=fundamental","pubTime":"2025-12-10 15:36","pubTimestamp":1765352183,"startTime":"0","endTime":"0","summary":"Capital Securities has issued a research report, stating that it has raised its profit forecast for Fosun Pharma (02196) to reflect the significant upfront payment that will boost profits. The firm...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0239","BK0060","BK1515","BK0175","BK0183","BK0188","02196","600196","BK0012","161027","BK0096","BK1191","BK1593","BK0187","BK0028"],"gpt_icon":0},{"id":"2590323891","title":"Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2590323891","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590323891?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:50","pubTimestamp":1765299000,"startTime":"0","endTime":"0","summary":"Pfizer on Tuesday joined the cavalcade of big pharma firms hunting for novel weight loss drugs in the laboratories of Chinese biotechs, even as U.S. authorities ramp up efforts to undercut the growing Chinese biotech sector.Pfizer said it had agreed to pay $150 million up front to a subsidiary of a large Chinese biopharma company called Shanghai Fosun Pharmaceutical Co. for the rights to an oral GLP-1 drug currently in early-stage human trials. The Fosun subsidiary, called Yao Pharma, could receive milestone payments worth up to $1.9 billion plus potential royalties as the program progresses.Now, to help round out its pipeline, Pfizer is looking to China, following the path trod by many of its peers in recent months. While the Metsera drugs closest to coming to market are injectables, the Yao drug Pfizer has now licensed could allow it to offer an oral option over the longer term.Those licensing deals have been particularly hot and heavy in the weight loss market: Merck licensed an ora","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","PFE","LU0203202063.USD","LU1127390331.HKD","LU2491049909.HKD","LU0109394709.USD","LU0417517546.SGD","LU1093756168.USD","IE00BK4W5L77.USD","LU2237443382.USD","LU0354030511.USD","LU2361044949.HKD","LU0198837287.USD","SGXZ31699556.SGD","IE00BFSS8Q28.SGD","IE00B1XK9C88.USD","IE00BZ1G4Q59.USD","SG9999002224.SGD","LU2168564222.USD","LU0882574139.USD","IE000M9KFDE8.USD","BK4585","LU0640476718.USD","LU1232071149.USD","IE00B775H168.HKD","LU2417539215.USD","BK4533","BK4581","BK4568","LU1868836757.USD","LU1323610961.USD","LU2552382215.SGD","LU0006306889.USD","SG9999015952.SGD","LU2362540622.SGD","BK4534","SG9999018857.SGD","LU0096364046.USD","IE0004445015.USD","LU0321505868.SGD","LU0353189763.USD","02196","LU0320765992.SGD","LU2462157665.USD","LU0225284248.USD","IE0005OL40V9.USD","LU1035775433.USD","LU2361044865.SGD","LU1280957306.USD","LU2456880835.USD","IE00B4JS1V06.HKD","LU2602419157.SGD","BK4139","LU0306806265.USD","LU1829250122.USD","LU2461242641.AUD","LU2063271972.USD","SG9999013999.USD","LU0154236417.USD","LU0266013472.USD","LU0689472784.USD","IE00BWXC8680.SGD","IE00BJJMRX11.SGD","IE00BJLML261.HKD","LU1069344957.HKD","LU2746668974.SGD","LU0820561909.HKD","LU0672654240.SGD","LU1551013425.SGD","SGXZ81514606.USD","IE00BKDWB100.SGD","SG9999003800.SGD","LU0170899867.USD","IE00BK4W5M84.HKD","IE00BKPKM429.USD","LU1720051017.SGD","LU2168564495.EUR","IE00BLSP4239.USD","BK4592","LU1291159041.SGD","LU0106261372.USD","LU0868494617.USD","LU2108987350.USD","LU2361045086.USD","LU0316494557.USD","IE00BKVL7J92.USD","IE00BN29S564.USD","LU0122379950.USD","LU2211815571.USD","LU1061106388.HKD","BK4007","LU0882574055.USD","LU2265009873.SGD","LU1983299246.USD","LU0823416689.USD","LU0354030438.USD","LU2552382058.USD","SG9999014914.USD","SGXZ99366536.SGD","SG9999014906.USD","IE00B7KXQ091.USD","LU1720051108.HKD","IE00B19Z3581.USD","LU2750360997.AUD","LU1868836914.USD","BK4599","LU0471298694.HKD","LU0323591593.USD","LU2168564149.EUR","SG9999011175.SGD","LU2552382132.HKD","LU1551013342.USD","LU0321505439.SGD","LU2237443895.HKD","LU0353189680.USD","GB00BDT5M118.USD","LU0289739699.SGD","LU2112291526.USD","IE00BFSS7M15.SGD","LU0320765059.SGD","LU1988902786.USD","LU2168563687.JPY","LU1814569148.SGD","BK4550","IE00BJJMRY28.SGD","LU2746668461.USD","SG9999001176.USD","LU1974910355.USD","LU2362541273.HKD","LU0238689110.USD","SG9999017495.SGD","LU0234572021.USD","LU1267930730.SGD","IE00BJJMRZ35.SGD","600196","LU0432979614.USD","LU1804176565.USD","SG9999015945.SGD","LU1883839398.USD","IE0002270589.USD","LU1093756325.SGD","IE00BBT3K403.USD","LU1894683264.USD","IE00BFTCPJ56.SGD","IE00B19Z3B42.SGD","LU1868837300.USD","IE00BJT1NW94.SGD","LU2237443978.SGD","IE00B2B36J28.USD","LU2324357040.USD","SG9999002232.USD","LU0061475181.USD","LU1868836591.USD","LU1064131342.USD","LU2237443622.USD","IE0002141913.USD","LU0079474960.USD","LU0456855351.SGD","LU1066053197.SGD","LU1066051498.USD","LU1023059063.AUD","LU2468319806.SGD","LU1548497426.USD","LU1712237335.SGD","LU0306807586.USD","LU0471298777.SGD","LU2491050154.USD","LU0058720904.USD","LU1894683348.USD","LU0109391861.USD","LU0786609619.USD","SG9999014880.SGD","LU0094547139.USD","LU2491050071.SGD","LU2362541513.USD","IE0009355771.USD","LU2471134879.HKD","LU0385154629.USD","IE00B4R5TH58.HKD","LU2237443465.HKD","LU2471134796.USD","LU0256863811.USD","LU0823434740.USD","IE00B1BXHZ80.USD","LU0097036916.USD","SGXZ57979304.SGD","SG9999015978.USD","LU1623119135.USD","LU0889565916.HKD","LU2471134952.CNY","BK4516","BK4588","LU0256863902.USD","LU1917777945.USD","SG9999001176.SGD","LU2750360641.GBP","SG9999014898.SGD","LU0823434583.USD","LU2106854487.HKD","IE00BLSP4452.SGD","LU2087625088.SGD","SGXZ51526630.SGD","LU1989771016.USD","LU0466842654.USD","LU2237443549.SGD","LU2360106947.USD","SG9999018865.SGD","LU0114720955.EUR","BK4532","LU2471134523.USD","LU2023250504.SGD","LU0053666078.USD","LU2236285917.USD","LU0225771236.USD","LU0820561818.USD","SG9999015986.USD","LU2264538146.SGD","LU1366192091.USD","LU2168564065.EUR","IE0004445239.USD","LU0708995401.HKD","LU1057294990.SGD","LU0943347566.SGD","LU2357305700.SGD","LU2237438978.USD","LU0203201768.USD","LU0985481810.HKD","LU1868837136.USD"],"gpt_icon":1},{"id":"1121382172","title":"FOSUN PHARMA (600196.SH): HLX22 Combined with HLX87 Injection Receives Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1121382172","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121382172?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:15","pubTimestamp":1765282519,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively referred to as \"Henlius\") recently received approval from the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK0096","BK0188","02196","BK0028","BK0060","BK1191","BK0183","BK0196","600196","BK0175","BK0187","BK1515","BK0239","BK0012"],"gpt_icon":0},{"id":"2590527343","title":"Fosun Pharma Subsidiary Yao Pharma Grants Pfizer Exclusive Global License for Oral GLP-1R Agonists","url":"https://stock-news.laohu8.com/highlight/detail?id=2590527343","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590527343?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:56","pubTimestamp":1765281403,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  Co. Ltd. announced that its subsidiary, Chongqing Yao Pharmaceutical Company, Limited , has entered into an exclusive collaboration and license agreement with Pfizer Inc. Under the agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor  agonists, including YP05002. Yao Pharma will receive an upfront payment of $150 million and is eligible for milestone payments of up to $1.935 billion, as well as tiered royalties on sales if approved. Yao Pharma will complete an ongoing Phase 1 clinical trial of YP05002 in Australia before Pfizer takes over further development and commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"6692cc092fbadfcafce950a9c4d79e01","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDLb0D0cj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0175","02196","LU1894683348.USD","LU0868494617.USD","BK0096","SG9999002232.USD","BK1230","BK4007","BK4534","LU0321505868.SGD","BK4533","LU0985481810.HKD","BK0028","LU1894683264.USD","IE00B19Z3B42.SGD","BK4568","SG9999002224.SGD","BK0183","SG9999003800.SGD","LU0122379950.USD","LU0170899867.USD","PFE","LU0289739699.SGD","BK4588","BK0187","LU1066053197.SGD","BK4599","SG9999001176.USD","SG9999013999.USD","SGXZ57979304.SGD","BK4581","LU1057294990.SGD","LU0225771236.USD","BK0188","IE0002270589.USD","IE00BBT3K403.USD","LU0058720904.USD","BK0012","BK4592","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0456855351.SGD","IE00BLSP4239.USD","LU0225284248.USD","LU0306806265.USD","LU0234572021.USD","LU1883839398.USD","BK0239","BK0060","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","600196","LU0306807586.USD","LU1066051498.USD","BK4585","LU1023059063.AUD","SG9999011175.SGD","BK4550"],"gpt_icon":1},{"id":"2590343548","title":"Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter Into Exclusive Collaboration and License Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343548?lang=en_us&edition=fundamental","pubTime":"2025-12-09 19:55","pubTimestamp":1765281346,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"97c84f3614faa6f5509f6dc6c1abfa42","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA3J6W06:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK0096","BK0196","600196","BK0060","BK0175","BK0187","BK0188","BK0183","BK0239","BK0012"],"gpt_icon":0},{"id":"2590931082","title":"Fosun Pharmaceutical Says Unit to Receive Upfront Payment of $150 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2590931082","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590931082?lang=en_us&edition=fundamental","pubTime":"2025-12-09 18:57","pubTimestamp":1765277829,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4N3XF0RC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0321505439.SGD","LU0985481810.HKD","SG9999002224.SGD","BK4599","IE00BBT3K403.USD","LU1894683264.USD","IE00B19Z3B42.SGD","BK0175","LU0058720904.USD","LU0306806265.USD","BK0196","SG9999003800.SGD","LU1066053197.SGD","IE0002270589.USD","BK4585","BK0028","IE00BLSP4239.USD","LU0234572021.USD","LU1894683348.USD","LU0225284248.USD","BK0239","LU0122379950.USD","BK4581","BK0187","BK0060","IE00B19Z3581.USD","BK0188","BK4007","LU0306807586.USD","IE00BLSP4452.SGD","SG9999001176.USD","BK4592","SG9999001176.SGD","LU0289739699.SGD","IE000M9KFDE8.USD","LU0321505868.SGD","BK0012","LU0170899867.USD","BK0096","LU1023059063.AUD","SG9999011175.SGD","LU1883839398.USD","BK4588","SGXZ57979304.SGD","BK4534","BK4550","LU0456855351.SGD","LU1057294990.SGD","LU0225771236.USD","BK4568","LU0868494617.USD","600196","SG9999013999.USD","LU1066051498.USD","SG9999002232.USD","02196","BK4533","BK0183"],"gpt_icon":0},{"id":"2590310755","title":"BRIEF-Fosun Pharmaceutical Says Unit Signs Licensing Agreement With Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590310755","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590310755?lang=en_us&edition=fundamental","pubTime":"2025-12-09 18:57","pubTimestamp":1765277829,"startTime":"0","endTime":"0","summary":"BRIEF-Fosun Pharmaceutical Says Unit Signs Licensing Agreement With PfizerDec 9  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:SAYS UNIT SIGNS GLP-1R LICENSING AGREEMENT WITH PFIZERSAYS UNIT TO RECEIVE UPFRONT PAYMENT OF $150 MILLIONSource textFurther company coverage: 600196.SS  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"97c84f3614faa6f5509f6dc6c1abfa42","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nL4N3XF0RC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","LU0306807586.USD","IE00BBT3K403.USD","SG9999003800.SGD","LU1894683348.USD","BK4585","BK4581","SG9999011175.SGD","LU1894683264.USD","LU0289739699.SGD","LU0225284248.USD","LU0058720904.USD","LU0170899867.USD","BK0187","IE00BLSP4239.USD","LU0234572021.USD","LU0225771236.USD","LU0321505868.SGD","IE00B19Z3581.USD","LU1883839398.USD","BK4592","LU0985481810.HKD","SG9999002232.USD","LU0122379950.USD","BK0196","BK0239","BK0028","IE000M9KFDE8.USD","IE0002270589.USD","BK0175","IE00BLSP4452.SGD","BK0060","IE00B19Z3B42.SGD","LU0456855351.SGD","SG9999002224.SGD","LU1023059063.AUD","LU1057294990.SGD","BK4550","600196","LU0868494617.USD","BK4534","BK4007","LU0321505439.SGD","LU1066051498.USD","SG9999013999.USD","BK4568","BK4588","BK4599","BK0183","BK0188","BK4533","SG9999001176.SGD","SG9999001176.USD","BK0012","LU1066053197.SGD","SGXZ57979304.SGD","LU0306806265.USD","BK0096"],"gpt_icon":0},{"id":"2589080384","title":"Fosun Pharmaceutical's Seven Drugs Included in China's Insurance Drug List","url":"https://stock-news.laohu8.com/highlight/detail?id=2589080384","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589080384?lang=en_us&edition=fundamental","pubTime":"2025-12-08 14:51","pubTimestamp":1765176664,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  and its subsidiaries included or adjusted the details of seven drugs in China's National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance list, according to a Monday disclosure on the Shanghai bourse.The drugs in the list are luvolimatinib tablets, vosvesi citrate capsules, pyronpanet oral Suspension, Tenapanor Hydrochloride Tablets, putomani tablets, keppra hydrochloride tablets and filgrastim-aafi injection.The list will take effect on Jan. 1, 2026.The pharmaceutical company's Shanghai shares rose more than 1% during Monday's afternoon trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","BK0060","BK0012","BK0028","BK0188","BK0196","BK0187","BK0175","BK0239","BK0096","BK0183"],"gpt_icon":0},{"id":"2588071955","title":"Fosun Pharma Gets Greenlight for Tumor Drug Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2588071955","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588071955?lang=en_us&edition=fundamental","pubTime":"2025-12-04 10:22","pubTimestamp":1764814970,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (SHA:600196) subsidiary Fosun Pharma Industrial obtained the approval of China's drug administrator to conduct a clinical trial of FXS887 tablets for treating advanced malignant solid tumors, according to a Wednesday filing with the Shanghai bourse.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0012","BK0183","600196","BK0187","BK0028","BK0188","BK0096","BK0175","BK0196","BK0060","BK0239"],"gpt_icon":0},{"id":"2588042065","title":"BRIEF-Shanghai Fosun Pharma's Unit Received Approval From NMPA For Clinical Trial Of Fxs887 Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2588042065","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588042065?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:44","pubTimestamp":1764773073,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma's Unit Received Approval From NMPA For Clinical Trial Of Fxs887 TabletsDec 3  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:UNIT RECEIVED APPROVAL FROM NMPA FOR CLINICAL TRIAL OF FXS887 TABLETSFurther company coverage: 600196.SS ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X80ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0183","BK0188","600196","BK0239","BK0096","BK0028","BK0012","BK0187","BK0175","BK0196"],"gpt_icon":0},{"id":"2588997012","title":"Shanghai Fosun Pharma -  Unit Received Approval From Nmpa for Clinical Trial of Fxs887 Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2588997012","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588997012?lang=en_us&edition=fundamental","pubTime":"2025-12-03 17:55","pubTimestamp":1764755713,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X80ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0183","BK0096","BK0187","BK0175","BK0028","BK0188","BK0060","BK0012","BK0196","BK0239","600196"],"gpt_icon":0},{"id":"2588909126","title":"Fosun Pharmaceutical Gets Acceptance for Drug Registration Application for Denosumab Biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2588909126","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588909126?lang=en_us&edition=fundamental","pubTime":"2025-12-03 12:04","pubTimestamp":1764734678,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical (SHA:600196) said China's drug regulator accepted the drug registration application for its denosumab biosimilar HLX14, according to a filing with the Shanghai bourse.Denosumab treats osteoporosis and various bone-related disorders.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0096","BK0060","BK0188","BK0187","BK0196","BK0183","BK0239","600196","BK0012","BK0028"],"gpt_icon":0},{"id":"2588091305","title":"Fosun Pharmaceutical Gets Regulatory Acceptance for Anticoagulant Registration Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2588091305","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588091305?lang=en_us&edition=fundamental","pubTime":"2025-12-03 11:47","pubTimestamp":1764733623,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  said China's drug regulator accepted the drug registration application for subsidiary Suzhou Erye's heparin sodium injection, according to a filing with the Shanghai bourse.The anticoagulant is intended for a wide range of uses, including preventing thrombosis, treating embolic complications, and supporting surgical and dialysis procedures.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0188","BK0196","BK0187","BK0060","600196","BK0175","BK0012","BK0096","BK0028","BK0239"],"gpt_icon":0},{"id":"2588624059","title":"BRIEF-Shanghai Fosun Pharma Says Liu Yi Elected As Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2588624059","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588624059?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:15","pubTimestamp":1764684916,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Says Liu Yi Elected As Executive Director Dec 2 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:LIU YI ELECTED AS EXECUTIVE DIRECTOR OF TENTH SESSION OF BOARDFurther company coverage: 600196.SS ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80FG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0060","BK0183","BK0188","600196","BK0239","BK0096","BK0028","BK0012","BK0187","BK0175","BK0196"],"gpt_icon":0},{"id":"2588056676","title":"BRIEF-Shanghai Fosun Pharma Says Drug Application Of Heparin Sodium Injection Accepted By NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056676","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056676?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:51","pubTimestamp":1764683480,"startTime":"0","endTime":"0","summary":"BRIEF-Shanghai Fosun Pharma Says Drug Application Of Heparin Sodium Injection Accepted By NMPADec 2  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:DRUG APPLICATION OF HEPARIN SODIUM INJECTION SUBMITTED BY UNIT ACCEPTED BY NMPAFurther company coverage: 600196.SS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0175","BK0060","BK0188","BK0012","BK0196","BK0096","BK0239","BK0187","600196","BK0028"],"gpt_icon":0},{"id":"2588058705","title":"Shanghai Fosun Pharma -  Drug Application of Heparin Sodium Injection Submitted by Unit Accepted by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2588058705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588058705?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:45","pubTimestamp":1764679521,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nFWN3X80FW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0060","BK0096","BK0196","BK0175","BK0239","BK0183","BK0012","BK0028","BK0187","BK0188","600196"],"gpt_icon":0},{"id":"2588788058","title":"Fosun Pharma Subsidiary Wins Acceptance for Drug Registration Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2588788058","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588788058?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:44","pubTimestamp":1764679492,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical Announces Acceptance of Subsidiary's Drug Registration Application. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL7b6fkZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK1230","BK0060","BK0239","BK0012","BK0188","600196","BK0028","BK0196","BK0096","00656","BK0183","BK0175"],"gpt_icon":0},{"id":"1175031278","title":"FOSUN PHARMA (02196): Liu Yi Elected as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1175031278","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175031278?lang=en_us&edition=fundamental","pubTime":"2025-12-02 19:52","pubTimestamp":1764676331,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) announced that Mr. Liu Yi has been formally elected as an executive director of the 10th Board of Directors during an extraordinary general meeting. His appointment took effect on December 2, 2025, and will last until the end of the current Board's term.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","BK1593","BK1191","BK0012","BK0060","BK0188","BK0239","BK0183","BK1515","BK0196","BK0028","600196","BK0187","BK0175","BK0096"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":0.0582},{"period":"1month","weight":-0.0028},{"period":"3month","weight":-0.0945},{"period":"6month","weight":0.1186},{"period":"1year","weight":0.0797},{"period":"ytd","weight":0.1618}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":-0.0006},{"period":"1month","weight":-0.0323},{"period":"3month","weight":0.0007},{"period":"6month","weight":0.147},{"period":"1year","weight":0.1284},{"period":"ytd","weight":0.1556}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","serverTime":1765525587983,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction